CASI stock icon

CASI Pharmaceuticals
CASI

$3.50
31.09%
 

About: CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Employees: 243

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0% more funds holding

Funds holding: 18 [Q4 2023] → 18 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.19% less ownership

Funds ownership: 2.07% [Q4 2023] → 1.88% (-0.19%) [Q1 2024]

54% less capital invested

Capital invested by funds: $1.98M [Q4 2023] → $903K (-$1.08M) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$6
71%
upside
Avg. target
$6
71%
upside
High target
$6
71%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Sean Lee
71%upside
$6
Buy
Maintained
15 May 2024

Financial journalist opinion